Graft-versus-host disease (GVHD) is a major complication of bone marrow transplantation that can occur in either acute or chronic forms. Much of the long-term pathology seen in chronic GVHD is a result of autoantibody production. In the DBA/2 → B6D2F1 murine model of chronic GVHD, anti-ssDNA autoantibodies can be detected by 14 days post cell transfer. These autoantibodies are not observed in B6D2F1 recipients of cells from C57BL/6 or B10.D2 donors, which develop acute rather than chronic GVHD. Therefore, in this model, donor genetic factors predispose to the development of chronic GVHD in recipients. We performed a genetic analysis aimed at mapping donor loci that influence the magnitude of early autoantibody production in B6D2F1 recipients of cells from DBA/2 donor mice. Linkage analysis suggested an influence of two loci: a locus on chromosome 11 linked to D11Mit278 and a locus on chromosome 4 linked to D4Mit226. The locus on chromosome 11 also appeared to influence the development of renal pathology associated with chronic GVHD. Bone Marrow Transplantation (2000) 26, 931-938.
immune disease. 7, 9, 10, 15 For instance, a polymorphism in the IL-10 promoter has been correlated with a high level of IL-10 production that has been reported to augment the severity of systemic lupus erythematosus (SLE). 13 Recent studies suggest that genetic polymorphisms in immune effector molecules may also influence the development of GVHD. 5, [16] [17] [18] There are two types of GVHD, acute and chronic. Acute GVHD arises shortly after transplantation and is characterized by a cell-mediated immune response involving the skin, liver and gastrointestinal tract. 19 Chronic GVHD is characterized by sustained B cell activation and autoantibody production that may lead to renal pathology, chronic liver involvement, and symptoms similar to those of autoimmune connective tissue disease. 19, 20 To elucidate donor genetic factors that may predispose to the development of chronic GVHD, we have studied the parent → B6D2F1 murine model. In this model, DBA/2 lymphoid cells cause chronic GVHD in non-irradiated B6D2F1 recipients whereas C57BL/6, C57BL/10 or B10.D2 lymphoid cells induce acute GVHD. Both the DBA/2 and B10.D2 strains are H-2 d , suggesting that the major histocompatibility complex is not responsible for the differential disease progression seen in recipients of B10.D2 vs DBA/2 cells. Rather, we hypothesize that non-MHC donor genetic factors influence the course of GVHD in this model.
In previous studies we have identified two loci which influence the development of acute GVHD in the B6D2F1 model. [21] [22] [23] However, our studies indicated that additional loci are involved in predisposing recipients to the development of chronic GVHD. In this report, we describe the results of a linkage analysis aimed at mapping loci at which donor polymorphism influences the development of chronic GVHD. Using the presence of early, heightened levels of autoantibodies as a phenotypic marker of chronic GVHD development, we have mapped four putative locations of genes, which may influence the development of chronic GVHD.
Materials and methods

Mice
DBA/2, C57BL/6, B10.D2 and (C57BL/6 × DBA/2) F1 (B6D2F1) mice were obtained from The Jackson Laboratory (Bar Harbor, ME, USA) or Harlan Sprague Dawley (Indianapolis, IN, USA). (B10.D2 × DBA/2) F1, (B10.D2 × DBA/2) × DBA/2 backcross (DBA/2 BX) and (B10.D2 × DBA/2) × B10.D2 backcross (B10.D2 BX) mice were bred in the animal facility of the Department of Biology at Indiana University-Purdue University at Indianapolis (IUPUI).
Induction of GVHD
Lymphoid cells were isolated from the spleen and axillary, brachial and/or cervical lymph nodes of donor mice at 6-9 weeks of age. Red blood cells were lysed and the remaining lymphocytes were washed twice with Dulbecco's modified Eagle medium (Gibco BRL, Gaithersburg, MD, USA) supplemented with 0.1 mg/ml streptomycin, 100 units/ml penicillin, 0.07 mm 2-mercaptoethanol, 7.5 mm HEPES, 1.5 mm l-glutamine, 5% fetal calf serum, and 22 mm NaHCO 3 . Lymphocytes were suspended to a final concentration of 3.0 × 10 8 cells/ml in sterile saline. 1.2-1.5 × 10 8 cells were injected into the tail veins of non-irradiated B6D2F1 recipient mice.
Various murine strains were used as donors, as shown in Table 1 . GVHD is induced in the recipients of the DBA/2, C57BL/6, B10.D2, (B10.D2 × DBA/2) F1, B10.D2 BX and DBA/2 BX lymphoid cells by the MHC mismatch between these H-2 homozygous donors and the H-2 heterozygous B6D2F1 recipients.
Recipient mice were housed for 6 months in the animal facility in the Department of Biology at IUPUI. Mice were bled, via the retro-orbital sinus, at 14-15 days post cell transfer and the sera assayed for anti-ssDNA autoantibodies. Recipients were also monitored monthly for levels of proteinuria using albustix (Bayer, IN, USA). A urine sample containing р300 mg/dl of protein was considered a negative result. A sustained urinalysis of у2000 mg/dl of urinary protein was considered a positive indication of glomerulonephritis due to chronic GVHD.
Mice were sacrificed at 6 months post cell transfer and necropsy was performed to detect overt renal pathology. The presence of overt renal pathology was also considered a positive indication of chronic GVHD. 
No response − 
DNA isolation
Upon sacrifice, a segment approximately 1.5 cm in length was cut off the tip of the tails of the DBA/2 BX and B10.D2 BX donor mice and placed in individual tubes containing a solution consisting of 500 l of tail buffer (50 mm Tris HCl (pH 8), 100 mm EDTA, 100 mm NaCl and 1% SDS) supplemented with 50 l of proteinase K (10 mg/ml). Tubes were heated in a water bath at 50°C for several hours, vortexing occasionally and stored at 4°C overnight. The following day, the tubes were centrifuged for 5-8 min in a microcentrifuge. The supernatant was placed into another tube containing 500 l of phenol. The tubes were vortexed for 10 s and centrifuged again for 5-8 min. The aqueous layer was then transferred to a new tube containing 500 l of phenol and tubes were vortexed, then centrifuged for 5-8 min. The aqueous layer was transferred to a tube containing 500 l of chloroform, tubes were vortexed and centrifuged for 5-8 min and the aqueous layer was again transferred to a new tube. 500 l of ethanol (4°C) was slowly added to each tube. A glass pipet plugged with sealant was submerged into the tube and vigorously agitated until white strands of DNA were visible. The DNA was transferred to tubes containing 70% ethanol. The tubes were centrifuged for 5 min, the supernatant discarded and the DNA was permitted to dry overnight. The DNA was resuspended the following day in 500 l of Tris EDTA (10 mm Tris, 1 mm EDTA) and stored at 4°C.
Assessment of anti-ssDNA autoantibodies
Serum levels of anti-ssDNA autoantibodies in the B6D2F1 recipients were determined by ELISA. Calf thymus DNA (Sigma, St Louis, MO, USA) was suspended in Tris EDTA to a concentration of 1 mg/ml and then diluted 1/100 in citrate buffer (pH 7) (0.15 m NaCl, 15 mm sodium citrate, 3 mm sodium azide). The DNA solution was boiled for 10 min and cooled rapidly on ice to denature into ssDNA. To a 96-well, high binding, flat-bottom microtiter plate (Costar No. 9018), 50 l of the ssDNA solution was added to coat each well and the plate was incubated at 4°C overnight. The following day, the plate was emptied and washed five times with 200 l of phosphate buffered saline (PBS) (1.37 m NaCl, 30 mm KCl, 15 mm KH 2 PO 4 and 97 mm NaHPO 4 ). After the plate was washed, 200 l of 0.5% bovine serum albumin (Sigma) in PBS was added to each well and the plate was incubated at 38°C for 1.5 h. The plate contents were then discarded and the wells were washed five times with PBS supplemented with 0.2% tween 20 (PBS/0.2% tween). 50 l of a 1/200 dilution of each serum sample in PBS/0.2% tween was added in triplicate to the plate and the plate was incubated 1.5 h at 38°C. The plate was then emptied and washed five times with PBS supplemented with 0.05% tween 20 (PBS/0.05% tween). One hundred l of a 1/500 dilution of an alkaline phosphatase conjugated goat anti-mouse immunoglobulin (recognizing both heavy and light chains) (Southern Biotechnology Associates, AL, USA) in PBS/0.05% Tween was added to each well and the plate was incubated 1.5 h at 38°C. The plate was then emptied and washed five times with PBS and 100 l of 5-bromo-4-chloro-3-indolyl phosphate (Kirkegaard and Perry Laboratories, MD, USA), a liquid substrate for phosphatase-labeled conjugates, was added to each well and incubated (25°C) until the 1/100 dilution of the serum used to obtain the standard curve had an absorbance of 2.0 at 620 nm.
Serum from aged MRL-lpr/lpr mice was used as the positive control from which a standard curve was obtained. For semi-quantitative purposes, we arbitrarily assigned numerical values to each MRl-lpr/lpr dilution with 25 600 units correlating with a 1/100 dilution of the MRL-lpr/lpr serum. The absorbances obtained from the test sera were compared with the standard curve and a number of units interpolated from the curve and assigned to each sample, correcting for the dilution factor.
Polymerase chain reaction (PCR) analysis of simple sequence repeat polymorphisms (SSRPs)
One l of DNA was used in a 20 l reaction. No mineral oil was added to the PCR tubes. The PCR reaction mixture contained 20 m dNTPs, 0.17 m of both reverse and forward primers, 2 l of 10X buffer (100 mm Tris-HCL, pH 8.3, 500 mm KCl, 15 mm MgCl 2 , and 0.01% gelatin) and 0.25 units of Taq polymerase plus 0.025 l of anti-Taq antibody (7 m) (Clontech, Palo Alto, CA, USA). Sequences of all primers used are available from the Mouse Genome Database. 24 The following cycle was repeated 39 times: 95°C for 1 min, the appropriate annealing temperature for 1 min, and 72°C for 1 min plus 1 s per cycle. A final cycle with an extension phase of 10 min at 72°C followed the 39th cycle. The resulting product was run on a 4% Metaphor agarose gel (FMC Bioproducts, ME, USA) at 7.8 V/cm.
Results
Elevated serum levels of anti-ssDNA autoantibodies are detectable early in the development of chronic GVHD
It has been previously reported that approximately 14 days post cell transfer (DPT), elevated levels of anti-nuclear autoantibodies are detectable in the serum of mice developing chronic GVHD. 25, 26 To verify this observation, we analyzed serum levels of anti-ssDNA autoantibodies at 14-15 DPT in the recipients of lymphoid cells derived from a variety of donor strains, as shown in Figure 1 . Recipients of C57BL/6 (B6) and B10.D2 lymphoid cells, known to induce acute GVHD, showed very low levels of antissDNA autoantibodies in their serum. Indeed, the levels of these cells in the recipients were significantly below the levels seen in recipients of B6D2F1 cells (P Ͻ 0.001 by Mann-Whitney analysis). The recipients of DBA/2 lymphoid cells, known to induce chronic GVHD, showed significantly higher levels of serum anti-ssDNA autoantibodies than both the recipients of the B10.D2 or B6 cells (P Ͻ 0.0001 by Mann-Whitney) and the recipients of the B6D2F1 cells (P Ͻ 0.002). Recipients of (B10.D2 × DBA/2) F1 lymphoid cells had low levels of anti-ssDNA autoantibodies, similar to the recipients of B10.D2 or B6 cells, indicating that the phenotype of elevated levels of serum anti-ssDNA autoantibodies is expressed in a recessive manner.
Analysis of backcross mice
Since the serum anti-ssDNA autoantibody levels are distinctly different in B6D2F1 recipients of B10.D2 and DBA/2 lymphoid cells, it appeared that the donor non-MHC loci are influencing this early aspect of chronic GVHD. In order to further investigate this (B10.D2 × DBA/2) × DBA/2 backcross mice (DBA/2 BX) were used as donors. 1.2-1.5 × 10 8 lymphoid cells from DBA/2 BX donors were injected into B6D2F1 recipients to induce GVHD. Serum samples were obtained at 14-15 DPT and serum levels of anti-ssDNA autoantibodies were determined.
The distribution of serum anti-ssDNA autoantibodies in the recipients of the DBA/2 BX lymphoid cells is shown in Figure 2a . For comparative purposes, levels of anti-ssDNA autoantibodies in recipients of B10.D2 (or B6) and DBA/2 lymphoid cells are also shown. The distribution of antissDNA autoantibodies in recipients of cells from DBA/2 BX donors was significantly different from that in recipients of cells from B10.D2 (or B6) cells (P Ͻ 0.0001 by Mann-Whitney comparison) and recipients of DBA/2 cells (P Ͻ 0.0001 by Mann-Whitney).
As shown in Figure 2b , the distribution of anti-ssDNA autoantibodies in recipients of DBA/2 BX lymphoid cells was also different from the distribution in recipients of B10.D2 BX cells (P Ͻ 0.0001 by Mann-Whitney). As was expected, the recipients of the B10.D2 BX cells tended to have low levels of serum anti-ssDNA autoantibodies. While a significant number of recipients of cells from DBA/2 BX donors also showed low levels of anti-ssDNA autoantibodies, a significant proportion (19%) of these mice developed levels in the range of those observed when DBA/2 donors were used. These data suggest that genetic factors influencing anti-ssDNA autoantibody levels are segregating in the DBA/2 BX mice. Since only a low proportion of the DBA/2 BX mice induced levels of serum autoantibodies comparable to those observed in recipients of DBA/2 cells, it seems likely that a number of donor genetic loci may control this aspect of chronic GVHD development.
Linkage analysis
In order to identify the genetic factors influencing the level of anti-ssDNA autoantibodies in B6D2F1 recipients, linkage analysis was performed on DNA from the DBA/2 BX donors. A genomic scan on a subset of 44 DBA/2 BX donors was performed using 79 linkage markers spanning the 19 chromosomes, as shown in Table 2 . For each linkage marker, Mann-Whitney comparison of serum anti-ssDNA autoantibodies in recipients of cells from donor mice that were homozygous for DBA/2 alleles at that linkage marker vs those heterozygous at that marker was performed. From the initial scan, five markers, on chromosomes 3, 4, 5, 11 and 17, with possible linkage (Z у 2) to a locus influencing anti-ssDNA autoantibody levels were identified.
An additional 84 DBA/2 BX donors were genotyped for linkage markers on the five chromosomes implicated by the initial scan. In this more detailed analysis, loci on chromosome 3 were found to not be linked to the anti-ssDNA autoantibody phenotype. However, significant linkage to D11Mit278 (P Ͻ 0.0005 by Mann-Whitney) and D4Mit226 (P Ͻ 0.0005) was obtained (Table 3) . Analysis also suggested possible linkage to D17Mit93 (P Ͻ 0.002) and D5Mit275 (P Ͻ 0.005).
As shown in Figure 3 , the distribution of anti-ssDNA autoantibodies in recipients of cells from DBA/2 BX donors homozygous for DBA/2 alleles at both D11Mit278 and D4Mit226 was significantly different from that observed in recipients of cells from donors heterozygous at both marker loci (P Ͻ 0.0001 by Mann-Whitney analysis). 43% (18/42) of mice receiving cells from donors heterozygous at both loci developed the lowest levels of autoantibodies, compared to 6% (2/33) of the mice receiving cells from donors homozygous at both loci. On the other hand, 39% (13/33) of mice receiving cells from donors homozygous at both loci developed the highest levels of autoantibodies, compared to 5% (2/42) of mice receiving cells from donors heterozygous at both loci.
Assessment of renal pathology
Since increased levels of serum anti-nuclear autoantibodies can lead to renal pathology, we determined whether there was a correlation between donor genotype at any of the linkage markers implicated in this study and the development of renal disease. Of the 128 recipients of DBA/2 BX lymphoid cells, 24 developed chronic GVHD according to our criteria (у2000 mg/dl of urinary protein and/or overt renal pathology at necropsy). Eighteen (30%) of the 60 mice which were recipients of cells from donors homozygous for the D11Mit278 linkage marker developed overt renal pathology while only six (9%) of the 68 mice receiving cells from donors heterozygous at this marker developed overt, chronic GVHD ( 2 = 9.383, P Ͻ 0.002). This suggests that a locus on chromosome 11 linked to the D11Mit278 linkage marker may also be influencing the development of the renal pathology characteristic of chronic GVHD.
No similar linkage was found to markers on chromosomes 4, 5, or 17. However, this analysis was limited by the small number of recipients of cells from backcross donors that developed chronic GVHD. Therefore, we can not yet rule out the possibility that loci in these regions may also exert an effect on development of renal pathology. Anti-ssDNA autoantibodies (units) Figure 3 Comparison of the distribution of serum anti-ssDNA autoantibody levels 14-15 days post transfer in recipients of 1.2-1.5 × 10 8 cells from DBA/2 BX donors either homozygous at both D11Mit278 and D4Mit226 or heterozygous at both linkage markers.
Discussion
In the parent → B6D2F1 model of GVHD, the immune response begins in the same manner in all recipients, regardless of the donor cells injected. Upon T cell activation, IL-2, IL-4 and IL-10 are present in mice developing both acute and chronic GVHD. 27 However, by 14 days post cell transfer, the profile of cytokines found in the recipients of the DBA/2 lymphoid cells is very different from that found in the recipients of the B10.D2 (or B6) cells. 28 The recipients of the DBA/2 cells, that will go on to develop chronic GVHD, have a predominance of Th2 type cytokines associated with B cell activation and the humoral immune response. 28 Mice that receive lymphoid cells from either B10.D2 or B6 mice, that will not develop chronic GVHD, primarily possess Th1 type cytokines associated with T cell activation and the cellular immune response. 27 Likewise, by 15 DPT, mice developing chronic GVHD have significantly higher levels of serum anti-ssDNA autoantibodies than do recipients developing acute GVHD. 25, 27 This differential disease progression is clearly under the control of non-MHC donor genetic factors.
Our study mapped some genetic factors that enable DBA/2 lymphoid cells to induce elevated serum levels of anti-ssDNA autoantibodies in B6D2F1 recipients. We found evidence suggesting that loci on chromosomes 11 and 4 influence this early aspect of chronic GVHD. A locus on chromosome 11 appears also to influence the development of the renal pathology that is associated with chronic GVHD.
Our analysis suggested significant linkage to a large region of chromosome 11. This region of chromosome 11 has also been associated with other murine models of autoimmune diseases such as type 1 diabetes mellitus, 29 systemic lupus erythematosus (SLE) 30 and multiple sclerosis. with B cell activation and the humoral immune response, are encoded on chromosome 11 within the area implicated by our linkage analysis. It is easy to see how a polymorphism in any of these genes might influence cytokine levels and subsequently, the development of a disease resulting from chronic B cell activation such as chronic GVHD. Our data also suggest significant linkage to chromosome 4, which has previously been implicated in other diseases resulting from B cell hyperactivation such as IgM hypergammaglobulinemia 32 observed in NZB mice, SLE, 30,33 and type 1 diabetes mellitus. 29 It is encouraging that our previous study investigating genetic factors influencing development of GVHD in the B6D2F1 model also suggested linkage to a locus within this region of chromosome 4. 21 Potential candidate genes encoded in the area on chromosome 4 implicated in this study are shown in Figure 4b . There are two members of the tumor necrosis factor receptor superfamily, Tnfrsf8 and Tnfrsf9 encoding CD30 and 4-1BB, found within this region.
4-1BB has previously been implicated in promoting Th1 responses. 34 Increased serum levels of soluble CD30 have been correlated with Th2 cell activation and seen in chronic GVHD patients. 35 In multiple sclerosis, high levels of soluble CD30 are indicative of remission, presumably due to the down-regulation of the Th1 cell activation that leads to disease pathology. 36 Conceivably, polymorphisms in either 4-1BB or CD30 might influence the relative predominance of the Th1 vs Th2 subsets during development of GVHD.
Our data also suggested possible linkage to chromosomes 5 and 17. Further analysis is underway to determine if these loci play a significant role in the development of chronic GVHD. It is interesting that a locus on chromosome 5 has previously been associated with the development of SLE in the MRL-lpr/lpr murine model 37 since SLE and chronic GVHD share similar disease pathology. This raises the possibility that factors predisposing to development of SLE in individuals may also predispose to development of chronic GVHD after bone marrow transplantation.
Little information is available concerning the development of chronic GVHD in irradiated recipients of DBA/2 lymphoid cells. It has been reported that transfer of DBA/2 cells to irradiated B6D2F1 recipients results in colonic GVHD, 38 which shares a similar pathology with human inflammatory bowel disease. 39 However, information concerning the mechanism of this disease pathology is not available and the mice in these studies were not monitored for symptoms of chronic GVHD. It is therefore difficult to estimate whether the loci mapped in our study also influence development of GVHD in irradiated recipients. This will best be investigated once strains congenic at the loci identified in this study, are constructed. We are currently breeding these congenic strains.
At present, very little is understood about the etiology of chronic GVHD. Further study of the loci mapped in this project and determination of their identity will shed light on the mechanisms that lead to the development of chronic GVHD. This may eventually allow us to develop improved preventative or therapeutic approaches to treating this syndrome.
